Japan’s Market Expansion Rule Going Nowhere, But Hope Remains For Pricing Premium
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly’s John Lechleiter and Alfonso Zulueta, as representatives from PhRMA, pressed the Japanese government to make permanent a temporary program that benefits innovative products. PhRMA believes the “market expansion rule" is a disincentive compared to the premium pricing given for innovative products.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.